BARCELONA, Spain I January 17, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-GPC3 immunotherapeutics in R&D: Product Category: Antibody; Cells; Radiopharmaceuticals; RNA
This product provides basic information on immunotherapeutics in R&D targeting GPC33.
This product consists of:
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. GPC3 has been demonstrated as a viable target for CAR T-cell and NK cell therapy, T-cell engaging bispecific antibodies, immune checkpoint bispecific antibodies, antibody-drug conjugates and radiopharmaceuticals. The report “GPC3-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/gpc3-targeted-immunotherapy-pipeline-review/ About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing